01—Abstract
Summary
Summary of the 8-K filed July 8, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) has announced a significant addition to its Board of Directors with the appointment of Michael McDonnell, effective July 8, 2026.
Mr. McDonnell brings over 35 years of extensive financial leadership experience, including recent service as Chief Financial Officer at Biogen Inc. and prior CFO roles at IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. His appointment to the Board as a Class II director and to the Audit Committee is expected to bolster the company's financial oversight and strategic guidance.
This move, announced via a press release furnished with the 8-K filing, signals a continued focus on strengthening corporate governance and leveraging seasoned financial expertise. The filing also notes changes to committee memberships, with David Rubenstein moving from the Audit Committee to the Nominating and Corporate Governance Committee.
02—Key points
Key Highlights
- Michael McDonnell appointed to Moderna's Board of Directors, effective July 8, 2026.
- Mr. McDonnell brings over 35 years of financial leadership, including recent CFO roles at Biogen and IQVIA.
- He has been appointed to serve as a Class II director and a member of the Audit Committee.
- David Rubenstein has been appointed to the Nominating and Corporate Governance Committee, stepping down from the Audit Committee.
- The appointment is expected to enhance the company's financial oversight and governance.
- Mr. McDonnell's compensation will align with Moderna's Non-Employee Director Compensation Policy, including initial and annual equity grants.
- No reportable transactions or relationships exist between Mr. McDonnell and Moderna under Regulation S-K Item 404(a).
03—Questions
Frequently Asked Questions
Who is Michael McDonnell and what is his background?
Michael McDonnell is a seasoned financial executive with over 35 years of experience. Most recently, he served as the Chief Financial Officer of Biogen Inc. from August 2020 to February 2025. Prior to that, he held CFO positions at IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. He has been appointed to Moderna's Board of Directors and its Audit Committee.
What is the significance of Michael McDonnell's appointment to the Audit Committee?
Mr. McDonnell's appointment to the Audit Committee is significant as it brings a wealth of financial leadership and public company experience to the board's oversight of financial reporting, internal controls, and audit processes. His extensive background as a CFO at major companies suggests a strong capability to contribute to these critical functions.
How will Michael McDonnell be compensated?
Mr. McDonnell will receive compensation as a non-employee director in accordance with Moderna's Amended and Restated Non-Employee Director Compensation Policy. This includes an Initial Grant and a pro-rata portion of an Annual Grant, as detailed in the company's 2026 Proxy Statement.
Are there any conflicts of interest or related-party transactions with Michael McDonnell?
The filing states that there are no arrangements or understandings between Mr. McDonnell and any other person related to his appointment, nor are there any family relationships with any director or executive officer. Furthermore, there are no transactions or relationships between Mr. McDonnell and Moderna that are reportable under SEC Regulation S-K Item 404(a).
04—Continue